Daraxonrasib nearly doubles pancreatic cancer survival; EU approval recommended

The experimental RAS-targeting drug Daraxonrasib nearly doubled survival in pancreatic cancer patients, and a favorable EU recommendation could accelerate market access. The claim is based on trial data and regulatory review, but long-term efficacy and safety remain uncertain. This matters as it offers a new treatment option for a notoriously difficult cancer.